Oncopeptides Announces Melflufen Data Accepted for Presentation at 2019 ASCO Annual Meeting

Booking.com

Stockholm – May 15, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that data from its Phase 1/2 O-12-M1 study evaluating melflufen, a lipophilic peptide-conjugated alkylator belonging to the novel class of peptidase enhanced cytotoxics, in the treatment of relapsed/refractory multiple myeloma (RRMM) have been selected for poster presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4 in Chicago.
The data offers an analysis of time to next treatment (TTNT) in patients with RRMM who were treated with melflufen and

Source: Oncopeptides Announces Melflufen Data Accepted for Presentation at 2019 ASCO Annual Meeting

Booking.com
Booking.com

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.